|Bid||100.00 x 500|
|Ask||108.67 x 400|
|Day's range||102.79 - 105.53|
|52-week range||17.33 - 111.36|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||91.57|
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) generates revenues from collaboration agreements through which it receives product sales revenues, royalties, license fees, milestone payments, and contract research payments. In fiscal 2017, Nektar Therapeutics generated total revenues of $307.7 million compared with $165.4 million in fiscal 2016.
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating.
Take-Two Interactive Software Inc., SVB Financial Group and Nektar Therapeutics are joining the S&P 500 index, according to S&P Dow Jones Indices.
NEW YORK , March 9, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents ...
SAN FRANCISCO , March 7, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky , Ph.D., is scheduled to present at the upcoming ...
Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.
The San Francisco-based company said it had a loss of 21 cents per share. Losses, adjusted for asset impairment costs, were 14 cents per share. The results exceeded Wall Street expectations. The average ...
SAN FRANCISCO , March 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2017. Cash and investments in marketable ...
Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SAN FRANCISCO , Feb. 21, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2017, on Thursday, March 1, 2018, ...
Bristol-Myers will pay through the nose for a minority stake in a cancer drug in its early clinical stage. Here's why it could be worth the risk.